Gushengtang (HKG:2273) plans to repurchase its shares on the market for up to HK$200 million under the June 2024 granted repurchase mandate, a Friday Hong Kong bourse filing said.
The traditional Chinese medicine company was granted the repurchase mandate on June 18,, to repurchase up to a little over 24.5 million shares, representing 10% of the company's issued shares as of June 18.
The repurchase will be done from the filing date until the conclusion of the company's next annual general meeting.